Characterization of a  cohort of storage mite sensitized subjects

ConclusionsSM are a  common sensitization in the study population and should be included in standard skin prick test arrays. Cross sensitization to house dust mites is limited and nasal symptoms are most frequent. Nasal provocation testing is necessary to secure clinical diagnosis of allergy and further research is ne eded to evaluate the clinical relevance of the high sensitization rates found for intradermal testing.
Source: Allergo Journal International - Category: Allergy & Immunology Source Type: research

Related Links:

Women are more likely than men to have a positive skin prick response for penicillin allergy, new research shows, but only an oral test tells the truth about penicillin allergy, another expert argues.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Source Type: news
A drug approved by the U.S. Food and Drug Administration in July to treat oral ulcers in patients with Behcet's syndrome may be a candidate for helping people with treatment-refractory recurrent aphthous stomatitis, according to correspondence from Swiss doctors published Wednesday online in The New England Journal of Medicine.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Dental & Oral Health News Source Type: news
Source: Full Feed - Category: Consumer Health News Source Type: news
AbstractDupilumab (Dupixent®) is a fully human monoclonal antibody against the interleukin (IL)-4 receptor α subunit of IL-4 and IL-4/IL-13 receptor complexes. IL-4 and IL-13 are key cytokines in driving type 2 inflammation, a dominant and largely eosinophilic inflammatory pathway in asthma. Trials evaluating the efficacy of dupilumab in asthma include three pivotal, placebo-controlled, phase 3 or 2b tr ials of 24–52 weeks’ treatment duration in patients aged ≥ 12 years with moderate-to-severe asthma (inadequately controlled with medium-to-high dose inhaled corticosteroids) or severe asthma [d...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
Remarks by Anna Abram, Deputy Commissioner for Policy, Legislation, and International Affairs, to the Food Allergy Summit in Washington, DC on November 14, 2019
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news
Publication date: Available online 14 November 2019Source: Respiratory Medicine Case ReportsAuthor(s): Talha Mahmud, Muhammad Saqib, Zanobia Nasim Butt, Saira FatimaAbstractA 62-year-old man, suffering from bronchial asthma was evaluated due to intractable cough. His dyspnea was controlled but cough remained unresponsive to escalation of asthma management steps. Cough occurred in bouts especially during night time and was occasionally productive of mucoid sputum. Other than bilateral rhonchi on chest auscultation, remaining systemic examination was unremarkable. CT chest showed a mass lesion in the bronchus intermedius tha...
Source: Respiratory Medicine Case Reports - Category: Respiratory Medicine Source Type: research
Just one shot of an experimental antibody treatment allowed people with severe peanut allergy to eat about one peanut's worth of peanut protein two weeks later, the study found.
Source: WebMD Health - Category: Consumer Health News Source Type: news
Allergies can cause vertigo, but this is rare. In this article, we look at how dizziness, vertigo, and allergies are linked, and whether or not treating allergy symptoms can help resolve vertigo.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Allergy Source Type: news
ConclusionsConcomitant use of dupilumab with long-acting beta agonists used in combination with inhaled corticosteroids, improves clinical outcomes and quality of life in patients with moderate to severe asthma. Although dupilumab has a promising role in treatment of patients with asthma, it is still in the emerging stage for its acceptance globally. Ongoing studies will help to determine dupilumab's long-term efficacy and safety for its future extensive use.
Source: Current Therapeutic Research - Category: Drugs & Pharmacology Source Type: research
Condition:   Peanut Allergy Interventions:   Drug: INP20;   Drug: Placebo Sponsors:   InnoUp Farma S.L.;   Syntax for Science, S.L Not yet recruiting
Source: - Category: Research Source Type: clinical trials
More News: Allergy | Allergy & Immunology | Anaphylactic Shock | Asthma | Hay Fever | Sinusitis | Skin | Study